Sugi Predict

Sugi Predict / Compounds / SCHEMBL722476

SCHEMBL722476

SCHEMBL722476

COc1cc(C(=O)c2c[nH]c(-c3ccc(OCc4ccccc4)cc3)n2)cc(OC)c1OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 3/20 0.54
▸ HDAC1 Q13547 3/20 0.54
▸ HDAC7 Q8WUI4 3/20 0.54
▸ HDAC8 Q9BY41 3/20 0.54
▸ HDAC6 Q9UBN7 3/20 0.54
▸ PRMT5 O14744 1/20 0.47
▸ TUBB4A P04350 4/20 0.46
▸ TUBB P07437 4/20 0.46
▸ TUBA3C P0DPH7 4/20 0.46
▸ TUBA1B P68363 4/20 0.46
▸ TUBA4A P68366 4/20 0.46
▸ TUBB4B P68371 4/20 0.46
▸ TUBB3 Q13509 4/20 0.46
▸ TUBB2A Q13885 4/20 0.46
▸ TUBB8 Q3ZCM7 4/20 0.46
▸ TUBA3E Q6PEY2 4/20 0.46
▸ TUBA1A Q71U36 4/20 0.46
▸ TUBA1C Q9BQE3 4/20 0.46
▸ TUBB6 Q9BUF5 4/20 0.46
▸ TUBB2B Q9BVA1 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL725347 0.86 TUBB4A (0.56) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL723931 0.85 TUBB1 (0.57) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL725053 0.83 PDGFRB (0.50) HDAC3HDAC1HDAC7HDAC8HDAC6
SCHEMBL4422328 0.82 EGFR (0.46) HDAC3HDAC1HDAC7HDAC8HDAC6
SCHEMBL3469479 0.82 EGFR (0.47) HDAC3HDAC1HDAC7HDAC8HDAC6
SCHEMBL724651 0.81 TUBB4A (0.49) HDAC3HDAC1HDAC7HDAC8HDAC6
SCHEMBL725112 0.81 NR4A2 (0.50) PRMT5CHEK2MCL1L3MBTL1DHODH
SCHEMBL4422699 0.80 TUBB4A (0.50) HDAC3HDAC1HDAC7HDAC8HDAC6
SCHEMBL723964 0.80 TUBB4A (0.51) HDAC3HDAC1HDAC7HDAC8HDAC6
SCHEMBL724356 0.80 PDGFRB (0.49) HDAC3HDAC1HDAC7HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 — — US disclosed
CN-119548495-A Use of (substituted 1H-imidazol-4-yl) (3, 4, 5-trimethoxyphenyl) methanones for the treatment of coronaviruses 维鲁公司 2025-03-04 — — CN disclosed
EP-4504183-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS Veru Inc. (US) 2025-02-12 — — EP disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 — — US disclosed
CN-118984703-A Methods of treating influenza and poxvirus infections 维鲁公司 2024-11-19 — — CN disclosed
US-20240180879-A1 METHODS OF TREATING INFLAMMATION VERU INC. (US) 2024-06-06 — — US disclosed
EP-4320151-A1 METHODS OF TREATING INFLAMMATION Veru Inc. (US) 2024-02-14 — — EP disclosed
WO-2023196632-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 — — WO disclosed
US-20230321045-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 — — US disclosed
US-20230265081-A1 METHODS OF TREATING CORONAVIRUS VERU INC. (US) 2023-08-24 — — US disclosed
US-9334242-B2 Compounds for treatment of cancer GTX, INC. (US) 2016-05-10 — — US disclosed
US-8822513-B2 Compounds for treatment of cancer GTX, INC. (US) 2014-09-02 — — US disclosed
WO-2012027481-A9 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2013-10-10 — — WO disclosed
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-08-01 — — US disclosed
EP-2608671-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-07-03 — — EP disclosed
EP-2542081-A1 COMPOUNDS FOR TREATMENT OF CANCER Gtx, Inc. (US) 2013-01-09 — — EP disclosed
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2012-03-22 — — US disclosed
WO-2012027481-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2012-03-01 — — WO disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 — — US disclosed
WO-2011109059-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2011-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 HDAC3 39/4885HDAC1 19/4885HDAC7 29/4885
US-20120071524-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 HDAC3 39/4885HDAC1 19/4885HDAC7 29/4885
US-20240180879-A1 METHODS OF TREATING INFLAMMATION IL1B, PYCARD, TUBB1 HDAC3 116/4885HDAC1 244/4885HDAC7 200/4885
US-20130197049-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 HDAC3 39/4885HDAC1 19/4885HDAC7 29/4885
US-20230321045-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS TUBB3, TUBB1, TUBB HDAC3 377/4885HDAC1 348/4885HDAC7 124/4885
US-20230265081-A1 METHODS OF TREATING CORONAVIRUS TUBB3, TUBB1, TUBB HDAC3 120/4885HDAC1 337/4885HDAC7 436/4885
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 HDAC3 39/4885HDAC1 19/4885HDAC7 29/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 HDAC3 39/4885HDAC1 19/4885HDAC7 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.